Renee D. Gala
Known title: President & CEOCIK: 0001607737
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
Transaction History
| JAZZ | ▼ Sell | Open Market | 2,000 | $473K | 10/6/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,967 | $485K | 9/8/2026 | View on chart |
| JAZZ | ▼ Sell | Open Market | 2,000 | $486K | 9/8/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 4,835 | $1.1M | 6/30/2026 | View on chart |
| JAZZ | ▼ Sell | Gift | 600 | $0 | 6/3/2026 | View on chart |
| DXCM | ▲ Buy | Grant | 5,605 | $0 | 5/28/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 7,065 | $1.3M | 3/5/2026 | View on chart |
| JAZZ | ▲ Buy | Grant | 44,465 | $0 | 2/26/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 5,371 | $919K | 1/16/2026 | View on chart |
| JAZZ | ▲ Buy | Grant | 12,741 | $0 | 1/16/2026 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 80 | $13K | 12/5/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 18,808 | $0 | 8/7/2025 | View on chart |
| DXCM | ▲ Buy | Grant | 5,074 | $0 | 5/8/2025 | View on chart |
| DXCM | ▲ Buy | Grant | 5,720 | $0 | 3/6/2025 | View on chart |
| JAZZ | ▼ Sell | Other | 5,704 | $793K | 3/5/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 23,111 | $0 | 2/27/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 11,555 | $0 | 2/27/2025 | View on chart |
| JAZZ | ▲ Buy | Grant | 7,741 | $0 | 1/17/2025 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 3,300 | $405K | 1/17/2025 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 80 | $10K | 12/5/2024 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,736 | $200K | 4/5/2024 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 3,622 | $426K | 3/5/2024 | View on chart |
| JAZZ | ▲ Buy | Grant | 19,916 | $0 | 3/1/2024 | View on chart |
| JAZZ | ▲ Buy | Grant | 7,079 | $0 | 1/17/2024 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 3,204 | $382K | 1/17/2024 | View on chart |
| JAZZ | ▲ Buy | Grant | 772 | $0 | 11/10/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 6,000 | $790K | 5/18/2023 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,807 | $263K | 4/5/2023 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,557 | $222K | 3/5/2023 | View on chart |
| JAZZ | ▲ Buy | Grant | 12,784 | $0 | 3/3/2023 | View on chart |
| JAZZ | ▼ Sell | Open Market | 2,635 | $422K | 12/21/2022 | View on chart |
| JAZZ | ▼ Sell | Tax Withholding | 1,633 | $266K | 4/5/2022 | View on chart |
| JAZZ | ▼ Sell | Other | 720 | $111K | 3/5/2022 | View on chart |
| JAZZ | ▲ Buy | Grant | 11,730 | $0 | 3/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
JAZZ: Ziihera FDA win and leadership change shift company outlook
Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.
JAZZ: Ziihera FDA win and leadership change shift company outlook. Jazz Pharmaceuticals recently received FDA approval for Ziihera and underwent a leadership change, which analysts suggest may alter the investment case. The company is also diversifying its portfolio, changing the narrative around its earnings. While the stock is currently trading near its 52-week low, the average analyst target price remains significantly higher than the current market level.